MedComm | Engineered biomaterials for cancer immunotherapy

Cancer immunotherapy has recently drawn much attention for its potentiality on clinic. However, the problem of side effects induced by poor selectivity and high doses still exists. In this review, Lul....



MedComm | Plasma pTau181 as a biomarker for Alzheimer's disease

Alzheimer's disease (AD) is one of the most difficult neurological disorders, because there are no means of biomarkers to predict the disease progression, nor is there a cure. Recently, on Nature Medi....



MedComm | Zeolite in tissue engineering: Opportunities and challenges

As a microporous tectosilicate, zeolite has been well known for its potentiality in tissue engineering applications, especially when it comes to provide a biological microenvironment. However, researc....



MedComm | The challenges of the COVID‐19 pandemic: Approaches for the elderly and those with Alzheimer's disease

The COVID-19 outbreak has brought challenges to societies around the globe, especially for some special communities. In this article, Qing Zhang et al reviewed some unique challenges the elderly and p....



MedComm - Plasma therapy cured a COVID‐19 patient with long duration of viral shedding for 49 days

COVID-19 has spread worldwide since it began in late 2019, becoming a threat to global health. Recently, Li Tan et al reported a special case of a family cluster with a mild type of COVID‐19, in which....



MedComm Introduction

MedComm is a peer-reviewed, online open access (OA) journal. The journal publishes a wide variety of works that provide novel insights into all aspects of medicine on the basis of novelty, timeliness



Molecular Biomedicine Introduction

Molecular Biomedicine is a peer-reviewed, online open access (OA), multidisciplinary journal that publishes the pioneer works of biomedicine, emphasizing on pathogenic mechanism and innovative


Mol Biomed

Signal Transduction and Targeted Therapy Introduction

Signal Transduction and Targeted Therapy is an open access journal, which aims to accomplish timely publication of the latest discoveries and progress in both basic science and clinical research